In one study, it was reported that microglial neuropilin 1 (NRP-1), a receptor for placental growth factor semaphorin 3A, VEGFA, and tuftsin, could serve as a promising pharmacological target for patients with GBs (Miyauchi et al., 2018; Glinka and Prud’homme, 2008; Gelfand et al., 2014; Nissen et al., 2013; Majed et al., 2006; Andersen et al., 2021). The gene discussed is VEGFA; the disease is Guillain-Barre syndrome.